Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
SEK 0.29
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Very low or no dividends
Data is available to registered users only
Data is available to registered users only
About
Modus Therapeutics Holding AB (publ), a biotechnology company, develops a treatment for sepsis and septic shock in Sweden. Its lead product is Sevuparin, a polysaccharide to treat patients with sepsis and septic shock, which is under Phase Ib clinical study. The company was founded in 2011 and is headquartered in Stockholm, Sweden.
Company Valuation
Considering past and projected metrics, the stock is slightly 'cheaper' than its peers.
Data is available to registered users only
Buy
Sell